ClinicalTrials.gg
RecruitingNCT06883864ELEVATE-AFUpdated Mar 13, 2026

Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial

An interventional study of Catheter ablation plus medication and Medication in Atrial Fibrillation (AF), Catheter Ablation and Atrial Functional Mitral Regurgitation, sponsored by Beijing Anzhen Hospital. Recruiting at 17 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.

Planned enrollment
22nd of 24
146 · median 410
Started
2025
with 10 others
No phase
21 of 36
15 open now
Primary completion
2027-08
later than 10 of 25 live
Registered
18th of 36
by date

Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 22nd largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2025, is one of 21 with no phase, reaches primary completion later than 10 of the 25 other live ones, and was the 18th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) leads to atrial functional mitral regurgitation (MR) through mechanisms including mitral annular dilatation, systolic leaflet motion distance alteration, and contractility decrease. Compared with primary MR, atrial functional MR due to AF and other diseases tends to have a worse prognosis, with a higher risk of death and heart failure hospitalization. MR and AF co-exist and exacerbate left atrial dysfunction, further causing worse cardiac dysfunction, valvular regurgitation, and aggravating prognosis.

The best therapy for secondary MR is unclear because MR is only one component of the disease, and restoration of mitral valve competence is not curative. Catheter ablation improves symptoms and cardiac function in patients with AF, reduces risks of AF recurrence and hospitalization, as well as increases quality of life. For patients with AF combined with functional moderate-to-severe MR, previous observational studies have found that the severity of MR significantly reduced after taking catheter ablation to restore sinus rhythm. We hypothesized that catheter ablation would significantly improve the severity of MR in patients with severe atrial functional MR combined with persistent AF compared with drug therapy alone.

Read the detailed description

The ELEVATE-AF is a multi-center, open-label, parallel design, randomized controlled trial. Eligible subjects will be randomized in a 1:1 ratio to the catheter ablation combined with drug group or to the drug-alone group. A total of 146 patients with persistent atrial fibrillation and severe atrial functional mitral regurgitation (MR) (severity of moderate-to-severe [3+] or severe [4+]) will be enrolled at up to 17 investigational sites in China. The enrollment period is estimated to last approximately 18 months. The primary endpoint is the proportion of patients with residual MR of moderate [2+] or less assessed by transthoracic echocardiography at 3 months. MR severity is confirmed by the Echocardiography Core Lab according to the American Society of Cardiac Ultrasound criteria (mitral effective regurgitant orifice area [EROA)]≤20 mm2). The secondary endpoints evaluate: (i)all-cause mortality; (ii)cardiovascular hospitalization; (iii)undergoing interventional or surgical treatment of mitral valve; (iv)heart failure hospitalization or emergency room visit; (v)change in scores on the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire, and the 5-level EQ-5D version (EQ-5D-5L); (vi) freedom from any documented atrial arrhythmias lasting more than 30 seconds and atrial fibrillation burden. The safety endpoints include: (i)perioperative surgical complications (within 30 days after catheter ablation procedure); (ii)major bleeding (ISTH definition); (iii)stroke and systemic embolism.

As an extension of the ELEVATE-AF trial, ELEVATE-AF X study will conducted after 3-month follow-up of ELEVATE-AF. The ELEVATE-AF X study is designed as a prospective, multi-center, continued access registry study. The objective of the this study is to validate the long-term outcomes of catheter ablation procedure in patients with persistent AF and severe atrial functional MR. All patients will receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of ELEVATE-AF trial. Active follow-up of patients will be performed through 12 months.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Catheter Ablation
  • Atrial Functional Mitral Regurgitation

Keywords

  • atrial fibrillation
  • mitral regurgitation
  • catheter ablation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients were required to have moderate-to-severe or greater (≥3+) atrial functional mitral regurgitation assessed by transthoracic echocardiography within 14 days before randomization. Mitral regurgitation severity was graded by an echocardiography core-lab based on the American Society of Echocardiography criteria, specifically an effective regurgitant orifice area (EROA) ≥30 mm²
  2. Age 18-80 years
  3. Persistent atrial fibrillation diagnosed by
  4. ≥50% assessed by transthoracic echocardiography within 14 days before randomization(confirmed by the echocardiography core-lab)
  5. Left ventricular end-diastolic internal diameter ≤60 mm and left atrial anterior- posterior diameter ≤60 mm in echocardiographic parasternal long-axis view within 14 days before randomization(confirmed by the echocardiography core-lab)
  6. Agree to undergo catheter ablation and be able to undergo follow-up as required.

Exclusion criteria

Exclusion Criteria:

  1. paroxysmal atrial fibrillation, atrial fibrillation secondary to an apparently reversible cause, or with history of previous ablation;
  2. primary mitral valve pathology, including calcification, sclerosis, prolapse, flail, tendon cable rupture, valve degeneration, infective endocarditis, rheumatic lesions, or ischemic lesions;
  3. history of previous mitral valve surgery or transcatheter manipulation;
  4. mitral valve orifice area \<4 cm2;
  5. aortic valve disease requiring surgical or transcatheter intervention;
  6. untreated coronary artery disease requiring revascularization;
  7. history of previous myocardial infarction;
  8. previous definitive diagnosis of cardiomyopathies such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, arrhythmogenic cardiomyopathy, and infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, and nodular disease)
  9. echocardiographic evidence of intracardiac mass or thrombus;
  10. implant of cardiac device (pacemaker, implantable cardioverter defibrillator, cardiac resynchronization therapy device, or left atria appendage closure);
  11. hemodynamic instability requiring cardiac assist devices, intra-aortic balloon pump (IABP), or other hemodynamic support;
  12. any percutaneous cardiac intervention (percutaneous coronary intervention, transcatheter aortic valve replacement, etc.) within the 30 days prior to randomization,
  13. any cardiac surgery within the 6 months prior to randomization;
  14. active infections requiring current antibiotic therapy;
  15. a known or contradiction to procedure medications which cannot be adequately managed medically;
  16. to appropriate anti-coagulation therapy;
  17. (COPD) requiring continuous home oxygen therapy or chronic oral therapy;
  18. acute cerebrovascular accident within 30 days prior to randomization or Modified Rankin Score ≥ 4;
  19. symptomatic severe carotid stenosis (>70% by ultrasound);
  20. other planned surgical or interventional procedures within the next 3 months;
  21. liver failure;
  22. renal failure or dialysis status;
  23. pregnant or planning pregnancy within the next 3 months;
  24. \< 12 months (e.g., advanced malignant tumors);
  25. currently participating in other interventional studies;
  26. circumstances that, in the judgment of the researcher, make participation in this study unsuitable.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Catheter ablation plus medication group

    All patients assigned to the catheter ablation group will receive AF catheter ablation and receive the same medical therapy as the control group.

    Procedure: Catheter ablation plus medication · Procedure: (ELEVATE-AF X) experimental group

  • Active comparator
    Medication group

    All patients should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.

    Drug: Medication · Procedure: (ELEVATE-AF X) control group

Interventions

  • ProcedureCatheter ablation plus medication

    All patients will receive atrial fibrillation catheter ablation. They also should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.

  • Patients will receive guideline-directed medical therapy, anticoagulation, and rate control according to the guidelines for the management of AF and heart failure.

  • Procedure(ELEVATE-AF X) experimental group

    Subsequent ablations may be considered for patients with recurrence,and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.

  • Procedure(ELEVATE-AF X) control group

    All patients could receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the proportion of patients with residual MR of moderate [2+] or less assessed by transthoracic echocardiography at 3 months.

    The primary endpoint is the proportion of patients with residual MR of moderate \[2+\] or less assessed by transthoracic echocardiography at 3 months. MR severity is confirmed by the Echocardiography Core Lab according to the American Society of Cardiac Ultrasound criteria (mitral effective regurgitant orifice area \[EROA)\]≤20 mm2).

    Time frame: 3 month

Secondary outcomes

  1. all-cause mortality

    Time frame: 3 month

  2. cardiovascular hospitalization

    Time frame: 3 month

  3. undergoing interventional or surgical treatment of mitral valve

    Time frame: 3 month

  4. heart failure hospitalization or emergency room visit

    Time frame: 3 month

  5. Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) score change between baseline and 3 month

    Quality of life assessed by AFEQT questionaire

    Time frame: 3 month

  6. EuroQoL 5-Dimension 5-Level (EQ-5D-5L) score change between baseline and 3 month

    Quality of life assessed by EQ-5D-5L scale

    Time frame: 3 month

  7. freedom from any documented atrial arrhythmias lasting more than 30 seconds and atrial fibrillation burden

    Time frame: 3 month

  8. Change from baseline to 3 months in the 6-minute walk distance

    Time frame: 3 months

  9. (ELEVATE-AF X) the proportion of patients with residual MR of moderate [2+] or less assessed by transthoracic echocardiography

    Time frame: 12 month

  10. (ELEVATE-AF X) all-cause mortality

    Time frame: 12 month

  11. (ELEVATE-AF X) cardiovascular hospitalization

    Time frame: 12 month

  12. (ELEVATE-AF X) undergoing interventional or surgical treatment of mitral valve

    Time frame: 12 month

  13. (ELEVATE-AF X) heart failure hospitalization or emergency room visit

    Time frame: 12 month

  14. (ELEVATE-AF X) Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) score change between baseline and 12 month

    Quality of life assessed by AFEQT questionaire

    Time frame: 12 month

  15. (ELEVATE-AF X) EuroQoL 5-Dimension 5-Level (EQ-5D-5L) score change between baseline and 12 month

    Quality of life assessed by EQ-5D-5L scale

    Time frame: 12 month

  16. (ELEVATE-AF X) freedom from any documented atrial arrhythmias lasting more than 30 seconds and atrial fibrillation burden

    Time frame: 12 month

  17. (ELEVATE-X) Change from baseline to 12 months in the 6-minute walk distance

    Time frame: 12 months

Other outcomes

  1. perioperative procedural complications

    Time frame: 3 months

  2. major bleeding (ISTH definition)

    Time frame: 3 months

  3. stroke and systemic embolism

    Time frame: 3 months

  4. (ELEVATE-AF X) major bleeding (ISTH definition)

    Time frame: 12 month

  5. (ELEVATE-AF X) stroke and systemic embolism

    Time frame: 12 month

07

Study locations

12 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 27 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 19, 2025
StartActual
Apr 8, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
May 1, 2028
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06883864
Collaborators
Abbott
Responsible party
Chang sheng Ma (Director of Cardiology Department, Beijing Anzhen Hospital, Capital Medical University, Director of Beijing Cardiovascular Disease Prevention Office and Director of Department of Cardiology in Capital Medical University, Beijing Anzhen Hospital) — Principal investigator
First posted
Mar 19, 2025
Start date
Apr 8, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Mar 13, 2026

Study contacts

liu HE, MD
Contact
theliu@139.com
+86 13810720787
Caihua Sang, MD
Contact
Changsheng Ma, MD
principal investigator · Beijing Anzhen Hospital
Caihua Sang, MD
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion